An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia

Launched by QIANFOSHAN HOSPITAL · Nov 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called Azvudine to treat patients with COVID-19 pneumonia. The researchers want to see how effective and safe Azvudine is for different groups of patients, based on when they start taking the medication after testing positive for COVID-19. Patients will be divided into four groups: those who start Azvudine treatment within 48 hours of their positive test, those who start after 48 hours, those who receive a short course of treatment without their virus test turning negative, and a control group that does not receive Azvudine.

To be eligible for this study, participants must have a confirmed diagnosis of COVID-19 pneumonia and be able to take medication by mouth. However, certain individuals cannot participate, such as those who are pregnant, have severe liver damage, or are experiencing severe vomiting. If you join this study, you'll be monitored closely by healthcare professionals to assess how well the medication works for you and to ensure your safety throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with confirmed diagnosis of COVID-19 pneumonia
• • Patients with the ability to take medication orally
• Exclusion Criteria:
• • Severe vomiting and difficulty in taking oral medication or ingestion of drugs after oral administration
• • Suspected or confirmed active systemic infection other than COVID-19 pneumonia
• • Pregnant or lactating women
• • Patients with mental disorders
• • Patients with severe liver damage
• • Patients who are treated with small molecule drugs such as Nirmatrelvir Tablets/Ritonavir Tablets(co-packaged)
• • Patients who are treated with RNA-dependent RNA polymerase (RDRP) inhibitors (Junshipharma VV116, Ascletis Pharma Inc. Asc10, Kexing biopharm Shen26, and Molnupiravir).